Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
2.960
-0.040 (-1.33%)
At close: Nov 20, 2024, 4:00 PM
2.900
-0.060 (-2.03%)
Pre-market: Nov 21, 2024, 5:48 AM EST
Galmed Pharmaceuticals Employees
As of December 31, 2023, Galmed Pharmaceuticals had 8 total employees, including 3 full-time and 5 part-time employees. The number of employees decreased by 2 or -20.00% compared to the previous year.
Employees
8
Change (1Y)
-2
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$790,500
Market Cap
4.46M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Check-Cap | 85 |
| Sharps Technology | 57 |
| Sunshine Biopharma | 44 |
| Aptevo Therapeutics | 40 |
| Genprex | 26 |
| Purple Biotech | 20 |
| Portage Biotech | 7 |
| Creative Medical Technology Holdings | 4 |
GLMD News
- 2 months ago - Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PRNewsWire
- 2 months ago - Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - PRNewsWire
- 8 months ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 - PRNewsWire
- 8 months ago - Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis - PRNewsWire
- 1 year ago - Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study - PRNewsWire
- 1 year ago - Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering - PRNewsWire